Senior Correspondent, London
Ben's Feed
Feb 5, 2014

GSK upbeat on heart drug, cancer vaccine despite setbacks

LONDON (Reuters) – Two high-risk bets by GlaxoSmithKline on new ways to fight heart disease and cancer were dealt a double blow last year by dud clinical trials – but the company remains hopeful about both projects.

Chief Executive Andrew Witty said on Wednesday there were still “intriguing” opportunities for its heart drug darapladib and MAGE-A3 therapeutic cancer vaccine.

Feb 5, 2014

Dutch gene therapy pioneer raises $82 mln in U.S. IPO

Feb 5 (Reuters) – A small Dutch company behind the Western
world’s first approved gene therapy priced its shares above the
expected range in a U.S. stock offering on Wednesday, showing
the current investor appetite for biotechnology.

Amsterdam-based uniQure said it would sell 5.4
million shares at an initial public offering price of $17.00
each, netting it $81.9 million after expenses. It had previously
indicated a price range of $13.00 to $15.00.

Feb 5, 2014
Feb 5, 2014
Feb 5, 2014

GlaxoSmithKline forecasts better 2014 as drug R&D improves

LONDON (Reuters) – GlaxoSmithKline has predicted a pick-up in sales growth to around 2 percent this year as productivity in its drug research labs improves and pressure on sales in China moderates following a damaging bribery scandal.

Britain’s biggest drugmaker also said on Wednesday that it would stay market leader in the respiratory medicine market – a category it has dominated since the launch of Ventolin in 1969 – despite generic threats to its top-selling Advair drug.

Feb 4, 2014
Feb 3, 2014
Jan 30, 2014
Jan 28, 2014
Jan 27, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben